John Victor Heymach

This study compares spatial immune architectures in tumor and tumor-adjacent tissues of early-stage NSCLC, finding distinct immune cell densities, spatial patterns, and associations with genomic features and patient outcomes.

This study shows DLL3 expression level predicts response and long-term survival in SCLC patients treated with tarlatamab.

The paper identifies TCRs targeting HER2 mutations in NSCLC, showing they recognize mutant epitopes and maintain cytotoxic activity, offering a potential immunotherapy strategy.

This study identifies YAP1-positive cells in relapsed SCLC that exhibit drug tolerance and transition from SCLC to LCNEC-like features, losing some targets but gaining others.

This study clarifies that NOTCH1 acts as a tumor suppressor in head and neck cancer, reducing cancer stem cells and improving prognosis, despite conflicting prior reports.

This study compares imaging-based spatial transcriptomics platforms using FFPE tumor samples, finding differences in performance and highlighting factors affecting data quality.

This study shows that BRAFV600E-driven lung cancer requires ERBB receptor signaling via ligand-mediated activation, and combined inhibition of BRAFV600E and ERBB improves therapeutic outcomes.

This study identifies three distinct DDR phenotypes in SCLC associated with chemotherapy response and tumor evolution.

This study identifies molecular and immune features associated with response to anti-PD-(L)1 therapy in NSCLC using a cohort of 393 patients.

The paper investigates how anti-cancer immunity evolves from preneoplasia to invasive lung adenocarcinomas, identifying changes in immune response and molecular features that may facilitate immune evasion.

This study examines DNA methylation changes and intra-tumor heterogeneity in lung adenocarcinoma progression, finding increased methylation aberrations and immunosuppression in later-stage lesions.

This study shows that transcriptomic features, not genomic characteristics, drive the histologic phenotype of lung cancers.

This study examines genomic and TCR repertoire heterogeneity in SCLC, finding that lower TCR heterogeneity and mutational burden correlate with better survival.

The paper analyzes single-cell RNA-seq data to identify ACE2 expression patterns in human lung epithelial cells, finding high ACE2 expression in alveolar type II cells and co-expression with pathogen receptors.